Biologic and Clinical Perspectives on Thyroid Cancer | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …

Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …

Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are
driven by less common genomic alterations, registries provide complementary information …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

The rearranged during transfection (RET) proto-oncogene was identified in 1985 and, very
soon thereafter, a rearrangement named RET/PTC was discovered in papillary thyroid …

Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

The RET receptor tyrosine kinase is crucial for normal development but also contributes to
pathologies that reflect both the loss and the gain of RET function. Activation of RET occurs …

Hemophilia A is an X-linked genetic disorder caused by mutations in the F8 gene, which
encodes the blood coagulation factor VIII. Almost half of all severe hemophilia A cases result …

To ensure the high-fidelity transmission of genetic information, cells have evolved
mechanisms to monitor genome integrity. Cells respond to DNA damage by activating a …